At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 17 enrolled
Drug / intervention
Olopatadine hydrochloride ophthalmic solution, 0.2%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2%
In Brief
A Phase 4 clinical trial evaluating Olopatadine hydrochloride ophthalmic solution, 0.2% for Allergic Conjunctivitis. Completed, enrolled 17 participants across 1 site.
Detailed Summary
The purpose of this study is to descriptively evaluate the corneal structures of allergic conjunctivitis patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2012
First PostedOct 2012
Primary CompletionJul 2013
TodayJul 2026
First PostedOct 2, 2012
Enrollment StartSep 1, 2012
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 13.8 years ago
Interventions
Olopatadine hydrochloride ophthalmic solution, 0.2%drug